Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and ...
The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...
The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...
"For the majority of people with advanced EGFR-mutated NSCLC, we have highly effective targeted treatment options. However, for a minority with EGFR exon 20-mutated disease, these treatments don’t ...
If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called imfinzi (durvalumab). Immunotherapy ...
Dr. Jyoti Patel is back on the podcast to discuss the updates to the living guideline on therapy for stage IV NSCLC with driver alterations. She shares updated recommendations in the first- and second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results